Goal
Inhibit HIV-1 replication and provide a therapeutic or curative approach for AIDS patients
Problem
Human immunodeficiency virus (HIV) infection and AIDS
Concept Summary
A collection of studies reports that aqueous extracts from several medicinal herbs (e.g., Spirulina platensis, Calcium-Spirulan, Nigella sativa, Scutellaria baicalensis) exhibit antiviral activity against HIV-1 in vitro and, in isolated case reports, in vivo. The extracts are claimed to block viral entry or replication, leading to reduced viral load and, in some anecdotal cases, sustained seroreversion.
Detailed Description
The article surveys peer-reviewed papers, patents, and case studies. Key findings include: (1) Spirulina platensis aqueous extract reduces HIV-1 production by ~50 % at 0.3-1.2 ug ml^-^1 (EC_5_0) and shows a therapeutic index of 200-6000; (2) a purified polysaccharide-calcium polymer (Calcium-Spirulan) inhibits HIV-1 and other viruses by preventing viral attachment to cell membranes; (3) Scutellaria baicalensis contains baicalin/baicalein which suppress HIV infectivity; (4) Black seed (Nigella sativa) extract was reported in a single case study to achieve complete seroreversion. Patents describe extraction methods for baicalin and related flavonoids, but no large-scale clinical data are presented.
Principles
- Antiviral activity via inhibition of viral attachment
- Direct inactivation of viral particles
- Inhibition of viral replication pathways
- Immunomodulation
Scientific Domains
Materials
- Spirulina platensis (Arthrospira platensis) aqueous extract
- Calcium-Spirulan (polymerized sugar with sulfur and calcium)
- Nigella sativa (black seed) extract
- Scutellaria baicalensis (baicalin, baicalein, wogonin)
- Olive leaf extract (oleuropein)
- Oregano oil
- Turmeric curcumin
Mechanisms of Action
- Blockage of virus-cell membrane binding
- Polysaccharide-mediated viral particle aggregation
- Flavonoid-mediated inhibition of reverse transcriptase
- Enhancement of host immune response
Applications
- Therapeutic treatment of HIV infection
- Adjunctive support for AIDS patients
Claimed Performance
EC_5_0 0.3-1.2 ug ml^-^1 (Spirulina), therapeutic index 200-6000; complete seroreversion reported for black-seed extract in one patient
Experimental Evidence
In-vitro inhibition of HIV-1 replication in T-cell lines, PBMCs and Langerhans cells; animal studies showing improved survival after viral challenge; single case study of black-seed extract with sustained remission
Replication Status
No large-scale clinical trials reported; evidence limited to in-vitro studies, animal models and isolated case reports
Limitations
- Predominantly in-vitro data; lack of controlled clinical trials
- Dosage, safety, and pharmacokinetics not established
- Potential variability in herbal composition
Red Flags
- Claims of cure or seroreversion based on single case reports
- Absence of peer-reviewed randomized clinical trial data
- Potential for patients to for proven antiretroviral therapy
